Phase II trial of elliptinium in advanced renal cell carcinoma and carcinoma of the breast. Academic Article uri icon

Overview

abstract

  • Elliptinium, 100 mg/m2 i.v. weekly, was administered to 14 patients with advanced renal cancer and 4 with breast cancer. There were no responses in 11 adequately treated patients. An unexpectedly high incidence of xerostomia, allergic, and hemolytic reactions were observed, which resulted in cessation of the trial. Recent data suggest polymer formation occurs with reconstituted elliptinium, and further trials are warranted when a new formulation is available.

publication date

  • July 1, 1985

Research

keywords

  • Adenocarcinoma
  • Alkaloids
  • Antineoplastic Agents
  • Breast Neoplasms
  • Ellipticines
  • Kidney Neoplasms

Identity

Scopus Document Identifier

  • 0021924283

PubMed ID

  • 4037737

Additional Document Info

volume

  • 5

issue

  • 4